Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteMechanisms of action of therapeutic antibodies for cancerTrial watch: Immunostimulatory cytokines in cancer therapy.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.A highly functional synthetic phage display library containing over 40 billion human antibody clones.Tenascin-C: Exploitation and collateral damage in cancer managementImmunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Immunocytokines for cancer treatment: past, present and future.Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.The emerging quest for the optimal angiostatic combination therapy.Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.Evolving Strategies for Target Selection for Antibody-Drug Conjugates.Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Site-Specific Antibody Functionalization Using Tetrazine-Styrene Cycloaddition.Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Emerging classes of armed antibody therapeutics against cancer
P2860
Q28066935-353A1822-C1A9-4FD7-8A4C-BB4BC6AAA2CBQ28385366-4C432010-2A75-409B-9EFC-8E892ECE1DF3Q33880165-AC80303C-EFE9-47E2-83F7-6F6A2D831F86Q35163167-1F19889F-CE08-4157-A355-44ECC464943DQ35192223-8FBBA660-F563-480E-B5B9-DE0B96EB4760Q35577959-A52CCC55-3675-47BE-8F8E-7DAB27A013D0Q37485709-5EC002E5-AD89-4EFD-93A8-769F139FE1C3Q37560208-6318B03F-CE5C-4BA0-8474-F0206B0189D9Q38208953-A925303E-3A00-499F-8BE0-0C998919EEFFQ38268453-45CC6BCC-3F8C-42AD-AFD0-0CA322E696D8Q38726647-00E20CC7-20A1-4524-9FD9-A34DECA834D0Q38905573-7851A26D-2A2C-4232-A7E8-AE2DC60A4050Q38920359-32084AE6-9042-4468-BF4E-7E4BEBB5815AQ38998638-6303B79A-97B3-4F19-AE8F-10AD53D7D3BFQ39185087-A51E2F7B-8753-4089-8C41-F07D0FD4DEAAQ45225869-BA7F4A44-7E66-482E-BF98-D87F1A4A0674Q45869295-8B2895F4-0CF5-44D5-B542-D77CE56CFCD1Q48199774-F3FD63A8-6923-4D6B-B0CE-F51A3D792F2BQ49687675-481145F6-A712-4EB7-9A0D-67D37E998A23Q50592781-8529ECE5-5D0C-41CD-AC3C-4FFEF82C18E7Q50885364-91C48687-FFDA-4A83-BE0F-41DC2EAA48AEQ50962872-ABBE5691-EA67-4439-8633-3DC8D8D3D59FQ52691844-51392E98-FB01-4B65-932F-2FB2C4984A2BQ53499740-3779DF9F-D595-4469-8E84-AFB92B64B20EQ55354182-D98C9180-5906-4616-86D9-8BDAB91316A1Q57911948-75384AAD-7B0B-457B-A7E3-0C958E30AE9A
P2860
Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antibody-based delivery of int ...... gainst acute myeloid leukemia.
@en
Antibody-based delivery of int ...... gainst acute myeloid leukemia.
@nl
type
label
Antibody-based delivery of int ...... gainst acute myeloid leukemia.
@en
Antibody-based delivery of int ...... gainst acute myeloid leukemia.
@nl
prefLabel
Antibody-based delivery of int ...... gainst acute myeloid leukemia.
@en
Antibody-based delivery of int ...... gainst acute myeloid leukemia.
@nl
P2093
P2860
P1476
Antibody-based delivery of int ...... gainst acute myeloid leukemia.
@en
P2093
Christoph Schliemann
Katharina Frey
Katrin L Gutbrodt
Leonardo Giovannoni
Thomas Pabst
Wolfgang E Berdel
Wolfram Klapper
P2860
P304
P356
10.1126/SCITRANSLMED.3006221
P407
P50
P577
2013-09-01T00:00:00Z